Threshold eyes Ph III pancreatic trials for TH-302 despite OS significance miss
This article was originally published in Scrip
Executive Summary
Threshold Pharmaceuticals' stock price fell 19.7% on 17 September after it reported Phase IIb median overall survival (OS) data that were positive yet not statistically significant for the tumour hypoxia-targeting small molecule TH-302 in the treatment of pancreatic cancer. But a spokeswoman for the company said the clinical trial results nevertheless supported Phase III development.